FDA Accepts Samsung Bioepis' BLA for SB8 Bevacizumab Biosimilar Candidate
Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's Biologics License Application (BLA) under the 351(k) pathway for SB8, a biosimilar candidate referencing AVASTIN®i (bevacizumab). The BLA for SB8 was submitted by Samsung Bioepis in September 2019.
If approved, SB8 will be commercialized in the United States (US) by Merck & Co., Inc., Kenilworth, NJ, USA, which is known as MSD outside the US and Canada.
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology and hematology. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com and follow us on social media ? Twitter, LinkedIn.
i AVASTIN® is a registered trademark of Genentech Inc.
Ivy Rehab, a premier provider of outpatient musculoskeletal rehabilitative services and pediatric therapy nationwide, is pleased to announce its partnership with Hilltop Physical Therapy, further solidifying its reach in Virginia....
Aubex Therapeutics Inc., a pioneering biotechnology firm, today announced its official launch, heralding a new era in the battle against cancer. Under the guidance of Board Member and Interim CEO, Jeffrey Glazer, Aubex's initial program is focused on...
Front Line Medical Technologies Inc, a leader in innovative medical devices for emergency and trauma care, today announced that its innovative COBRA-OS® (Control Of Bleeding, Resuscitation, Arterial Occlusion System) has officially been granted CE...
Onyx Behavioral Health, a leading primary mental health residential treatment facility, alongside its parent company USR Holdings LLC, is excited to announce its participation in the 2024 Safety Festival at Clover Park in Port Saint Lucie on...
ZERO Prostate Cancer, the nation's leading prostate cancer organization, is pleased to announce the appointment of Brian Bragg as its first-ever Chief Mission Officer. Bragg, a distinguished expert in the healthcare and community health space, will...
